Aug 07, 2023 9:00am EDT 180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
Aug 03, 2023 8:00am EDT 180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
Jul 31, 2023 8:00am EDT 180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
Apr 10, 2023 4:30pm EDT 180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
Apr 05, 2023 1:00pm EDT 180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
Feb 23, 2023 7:30am EST 180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
Jan 25, 2023 8:45am EST 180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
Jan 17, 2023 8:00am EST 180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom